JP6144688B2 - インドールアルキルアミノ−ウィタステロイド複合体および使用方法 - Google Patents

インドールアルキルアミノ−ウィタステロイド複合体および使用方法 Download PDF

Info

Publication number
JP6144688B2
JP6144688B2 JP2014540198A JP2014540198A JP6144688B2 JP 6144688 B2 JP6144688 B2 JP 6144688B2 JP 2014540198 A JP2014540198 A JP 2014540198A JP 2014540198 A JP2014540198 A JP 2014540198A JP 6144688 B2 JP6144688 B2 JP 6144688B2
Authority
JP
Japan
Prior art keywords
compound
formula
complex
extract
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014540198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501787A5 (enExample
JP2015501787A (ja
Inventor
ゴーサル，シブナス
ヴィーララガヴァン，ムルガナンダム
カリディンディ，サンヤシ，アール．
Original Assignee
ナトレオン，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナトレオン，インコーポレイテッド filed Critical ナトレオン，インコーポレイテッド
Publication of JP2015501787A publication Critical patent/JP2015501787A/ja
Publication of JP2015501787A5 publication Critical patent/JP2015501787A5/ja
Application granted granted Critical
Publication of JP6144688B2 publication Critical patent/JP6144688B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2014540198A 2011-11-07 2012-11-06 インドールアルキルアミノ−ウィタステロイド複合体および使用方法 Expired - Fee Related JP6144688B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161556603P 2011-11-07 2011-11-07
US61/556,603 2011-11-07
US13/669,207 2012-11-05
US13/669,207 US9084800B2 (en) 2011-11-07 2012-11-05 Indolealkylamino-withasteroid conjugates and method of use
PCT/US2012/063727 WO2013070619A1 (en) 2011-11-07 2012-11-06 Indolealkylamino-withasteroid conjugates and method of use

Publications (3)

Publication Number Publication Date
JP2015501787A JP2015501787A (ja) 2015-01-19
JP2015501787A5 JP2015501787A5 (enExample) 2015-10-29
JP6144688B2 true JP6144688B2 (ja) 2017-06-07

Family

ID=48223848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540198A Expired - Fee Related JP6144688B2 (ja) 2011-11-07 2012-11-06 インドールアルキルアミノ−ウィタステロイド複合体および使用方法

Country Status (7)

Country Link
US (2) US9084800B2 (enExample)
EP (1) EP2776462B1 (enExample)
JP (1) JP6144688B2 (enExample)
CN (1) CN103917558B (enExample)
BR (1) BR112014010868B1 (enExample)
CA (1) CA2854631C (enExample)
WO (1) WO2013070619A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105503990A (zh) * 2015-12-29 2016-04-20 吴金凤 一种新的睡加内酯类化合物及其制备方法和医药用途
WO2018156202A1 (en) 2017-02-27 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-psychotic composition and treatment methods
CN119631978B (zh) * 2024-12-18 2026-06-30 云南洛宇生物科技有限公司 一种树鼩阿尔兹海默症造模方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494698A1 (fr) * 1980-11-21 1982-05-28 Roussel Uclaf Nouveaux derives steroides 3-amino substitues, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6153198A (en) * 1999-07-13 2000-11-28 Natreon Inc. Withania somnifera composition
EP1421198A4 (en) * 2001-06-26 2006-08-30 New York State Office Of Menta SCREENING METHODS WITH HIGH CYCLE-BASED FLOW
US6713092B1 (en) * 2002-12-03 2004-03-30 Natreon Inc. Withania Somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof
US20050266100A1 (en) * 2004-03-30 2005-12-01 Council Of Scientific And Industrial Research Rafi Marg Process isolation of withaferin-A from plant materials and products therefrom
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
JP2009541423A (ja) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
JP5704484B2 (ja) 2008-03-06 2015-04-22 独立行政法人産業技術総合研究所 アシュワガンダ葉水抽出物を有効成分として含む組成物及びその製造方法
WO2010030395A2 (en) 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof

Also Published As

Publication number Publication date
BR112014010868A8 (pt) 2020-04-22
US9084800B2 (en) 2015-07-21
US20150320771A1 (en) 2015-11-12
US20130115316A1 (en) 2013-05-09
BR112014010868B1 (pt) 2021-07-06
EP2776462A4 (en) 2015-04-08
WO2013070619A1 (en) 2013-05-16
CA2854631A1 (en) 2013-05-16
CA2854631C (en) 2018-12-11
EP2776462B1 (en) 2018-01-10
JP2015501787A (ja) 2015-01-19
CN103917558A (zh) 2014-07-09
WO2013070619A8 (en) 2014-05-08
CN103917558B (zh) 2017-04-12
US10449206B2 (en) 2019-10-22
BR112014010868A2 (pt) 2017-06-13
EP2776462A1 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
Zhu et al. 4-Hydroxybenzyl alcohol derivatives and their sedative–hypnotic activities
US12280030B2 (en) Method of using a chlorogenic acid composition for supporting cognitive function
Ajayi et al. Acetylcholinesterase inhibitor from Anthocleista vogelii leaf extracts
Karthivashan et al. Cognitive-enhancing and ameliorative effects of acanthoside B in a scopolamine-induced amnesic mouse model through regulation of oxidative/inflammatory/cholinergic systems and activation of the TrkB/CREB/BDNF pathway
EP2025335A1 (en) Extracts with liver-X-receptor modulators, compounds and their use in weight control and treatment of disorders of lipid metabolism
US10449206B2 (en) Indolealkylamino-withasteroid conjugates and method of use
JP4909984B2 (ja) リグナン系化合物の新規な用途
KR102661884B1 (ko) 해방풍 추출물 또는 이의 분획물을 유효성분으로 포함하는 경도인지장애 개선용 조성물
EP3639817B1 (en) Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases
ES2373509T3 (es) Dihidrochalcona similar a aspalatina, extractos de rooibos no fermentado y procedimiento de preparación.
KR100711028B1 (ko) 향나무 추출물 또는 세드롤을 포함하는 비만 및 제2형당뇨병 예방 및 치료용 조성물
KR101052594B1 (ko) 디아실 코에이:글리세롤 아실트랜스퍼라제 저해활성을 갖는감초 추출물, 이의 용매분획물 또는 이로부터 분리된 화합물을 포함하는 조성물
US8609151B2 (en) Treatment of erectile dysfunction and libido enhancement
CN113461702B (zh) 酰基间苯三酚低聚体其制备方法和应用
Heraiz et al. Dual inhibition of acetylcholinesterase and β-secretase by metabolites from Echinocactus grusonii Hildm.: in silico and in vitro investigations
KR100697235B1 (ko) 관동화 추출물 또는 투실라곤을 포함하는 비만 및 제2형당뇨병 예방 및 치료용 조성물
JP4157767B2 (ja) 退行性脳神経系疾患の予防および治療効果を有するハンゲショウ抽出物
KR20240164685A (ko) 뱀톱 추출물 또는 이로부터 분리한 화합물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 조성물
KR100615357B1 (ko) 인지력 향상효과를 갖는 신규 알칼로이드 유도체 화합물및 이를 함유하는 조성물
Ha et al. Tryptophan-derived Alkaloids from Hedera rhombea Fruits and Their Butyrylcholinesterase Inhibitory Activity
Acero et al. Cholinesterase Inhibitory Activities and In Silico Docking Studies of Blumeatin Isolated from Blumea balsamifera L. DC.
KR20260056041A (ko) 석곡 추출물 또는 이의 분획물로부터 얻은 화합물을 유효성분으로 포함하는 퇴행성 뇌질환 치료 또는 예방용 조성물
WO2024107995A1 (en) Ebelin lactone or bacogenin a1 enriched composition and method of preparation thereof
Cipra Biological activity of plants metabolites. XVII. Alkaloids of Corydalis yanhusuo WT WANG.
WO2013179309A1 (en) Novel compounds as memory enhancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170425

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170511

R150 Certificate of patent or registration of utility model

Ref document number: 6144688

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees